The Role of Metalloproteinases Their Inhibitors in Hematological Disorders

Critical Reviews in Oncogenesis

Volumn 7, Issue 3-4, 1996, Pages 205-225

  Guedez, Liliana ^a   Lim, Megan S ^a   Stetler Stevenson, William G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

ECM; Extracellular matrix; timps; Hematopoiesis; Inflammation; Leukocytemetalloproteinases; Soluble ligand receptors; Tissue inhibitors of metalloproteinases

Indexed keywords

BLOOD DISEASE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; EXTRACELLULAR MATRIX; HUMAN; PATHOGENESIS; PROTEIN SYNTHESIS REGULATION; REVIEW;

ANIMALS; CYTOKINES; HEMATOLOGIC DISEASES; HEMATOLOGIC NEOPLASMS; HEMATOPOIESIS; HUMANS; INFLAMMATION; LEUKOCYTES; LYMPHOCYTES; METALLOENDOPEPTIDASES; PROTEASE INHIBITORS; RECEPTORS, CELL SURFACE;

EID: 0030405381     PISSN: 08939675     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevoncog.v7.i3-4.40     Document Type: Article

References (177)

1. Albini, A., G. Fontanini, L. Masiello, C. Tacchetti, D. Bigini, P. Luzzi, D. M. Noonan, and W. G. Stetler-Stevenson: Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2. AIDS, 8:1237-1244 (1994).
2. Albini, A. G., R. Soldi, D. Giuciuglio, E. Giraudo, R. Benelli, L. Primo, D. Noonaan, M. Salio, G. Camussi, W. Rockland, and F. Bussolino: The angiogenesis induced by HIV TAT protein is mediated by the FLK 1/RBR receptor on vascular endothelial-cells. Nature Med., 12:1371-1375 (1996).
3. Alitalo, R., J. Partanen, L. Pertovaara, E. Holtta, L. Sistonen, L. Andersson, and K. Alitalo: Increased erythroid potentiating activity/tissue inhibitor of metalloproteinases and jun/fos transcription factor complex characterize tumor promoter-induced megakaryoblastic differentiation of K562 leukemia cells. Blood, 75:1974-821 (1990)
4. Anand-Apte, B., M. S., Pepper, E., Voest, R., Montesano, B. R., Olsen, G. Murphy, S. S., Apte, and B. Vetter: Inhibition of angiogenesis by tissue inhibitor of metalloproteinases-3. Invest. Opthalmol. Vis. Sci., in press (1997).
5. Andreasen, P. A., B. Georg, L. R. Lund, A. Riccio, and S. N. Stacey: Plasminogen activator inhibitors: hormonally regulated serpins. Mol. Cell Endocrinol., 68:1-19(1990).
6. Apte, S. S., K., Hayashi, M. F., Seldin, M-G., Mattei, M. Hayashi, and B. R. Olsen: Gene encoding a novel murine tissue inhibitor of metalloproteinases (TIMP), TIMP-3, is expressed in developing mouse epithelia, cartilage, and muscle and is located on mouse chromosome 10. Dev. Dynam., 200:177-197 (1994).
7. Apte, S. S., B. R. Olsen, and G. Murphy: The gene structure of tissue inhibitor of metalloproteinase (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J. Biol. Chem., 270:14313-14318 (1995).
8. Avalos, B. R., S. E. Kaufman, M. Tomonaga, R. E. Williams, D. W. Golde, and J. C. Gasson: K562 cells produce and respond to human erythroid-potentiating activity. Blood, 71:1720-1725(1988).
9. Aznavoorian, S., A. Murphy, W. G. Stetler-Stevenson, and L. Liotta: Molecular aspects of tumor cell invasion and metastasis. Cancer, 71:1368-1380 (1993).
10. Baricos, W. H., S. L. Cortez, S. S. el-Dahr, and H. W. Schnaper: ECM degradation by cultured mesangial cells is mediated by a PA/plasmin/MMP-2cascade. Kidney Int., 47:1039-1047(1995).
11. Bellgrau, D., D. Gold, H. Selawry, J. Moore, A. Franzusoff, and R. C. Duke: A role for CD95 in preventing graft rejection. Nature, 377:630-632 (1995).
12. Bertaux, B., W. Hornebeck, A. Z. Eisen, and L. Dubertret: Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J. Invest. Derm., 97:679-685 (1991).
13. Birkedal-Hansen, H.: Role of cytokines and inflammatory mediators in tissue destruction. J. Perioden. Res., 28:500-510 (1993).
14. Birkedal-Hansen, H., W. G. Moore, M. K. Bodden, L. J. Windsor, B. Birkedal-Hansen, A. DeCarlo, and J. A. Engler: Matrix metalloproteinases: a review. Crit. Rev. Oral Biol. Med., 4:197-250 (1993).
15. Borrego, F., A. Lopez-Beltran, J. Pena, R. Solana: Downregulation of Fc-gamma receptor III A alpha (CD16-II) on natural killer cells induced by anti-CD16 mAB is indepedent of protein tyrosine kinases and protein kinase C. Cell Immunol., 158:208-217 (1994).
16. Brown, P. D.: Section review-matrix metalloproteinase inhibitors: a new class of anticancer agent. Curr. Opin. Invest. Drugs, 2:617-626 (1993).
17. Brown, P. D.: Clinical trials of a low-molecular-weight matrix metalloproteinase inhibitor in cancer. Ann. N.Y. Acad. Sci., 732:217-221 (1994).
18. Brunner, G. and T. Preissner: Pericellular enzymatic hydrolysis: implications for the regulation of cell proliferation in the vessel wall and bone marrow. Blood Coagul. Fibrinol., 5:625-639 (1994).
19. Busiek, D. F., V. Baragi, L. C. Nehring, W. C. Parka, and H. G. Welgus: Matrilysin expression by human mononuclear phagocytes and its regulation by cytokines and hormones. J. Immunol., 154:6844-6849 (1995).
20. Bussolino, F., E. Bocchieto, F. Silvagno, R. Soldi, M. Arese, and A. Mantovani: Actions of molecules which regulate hematopoiesis on endothelial cells: memoirs of common ancestors? Path. Res. Pract., 190:834-839 (1994).
21. Campbell, E. J., J. D. Cury, S. D. Shapiro, G. I. Goldberg, and H. G. Welgus: Neutral proteinases of human mononuclear phagocytes. Cellular differentiation markedly alters cell phenotype for serine proteinases, metalloproteinases and tissue inhibitor of metalloproteinases. J. Immunol., 146:1286-1293 (1991).
22. Chandler, S., J. Cossins, J. Lury, and G. Wells: Macrophage metalloproteinase degrades matrix and myelin proteins and processes a tumor-necrosis-factor-lapha fusion protein. Biock. Bioph. Res. Comm., 228:421-429 (1996).
23. Chesler, L., D. W. Golde, N. Bersch, and M. Johnson: Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. Blood, 86:4506-4515 (1995).
24. Chirivi, R., A. Garofalo, M. Crimmin, L. Bawden, A. Stoppacciaro, P. Brown, and R. Giavazzi: Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int. J. Cancer, 58:1-5 (1994).
25. Clark, B. and A. Keating: Biology of bone marrow stroma. N.Y. Acad. Sci., 770:70-78 (1995).
26. Conca, W. and F. Willmroth: Human T lymphocytes express a member of the matrix metalloproteinase gene family. Arthritis and Rheum., 37:951-956 (1994).
27. Corcoran, M. L. and W. G. Stetler-Stevenson:. Tissue inhibitor of metalloproteinases-2 (TIMP-2) stimulates fibroblast proliferation via a cyclic adenosine 3′,5′-monophosphate (cAMP)-dependent mechanism. J. Biol. Chem., 270:13453-13459 (1995).
28. Davies, B., P. D. Brown, N. East, M. J. Crimmin, and F. R. Balkwill: A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res., 53:2089-2091 (1993).
29. De Bart, A. C., P. H. Quax, C. W. Lowick, and J. H. Verheijen: Regulation of plasminogen activation, matrix metalloproteinases and urokinase-type plasminogen activator-mediated matrix degradation in human osteosarcoma cell line MG63 by interleukine 1-alpha. J. Bone Miner. Res., 10:1374-1384 (1995).
30. DeClerck, Y. A., T-D. Yean, Y. Lee, J. M. Tomich, and K. E. Langley: Characterization of the functional domain of tissue inhibitor of metalloproteinases-2 (TIMP-2). Biochem. J., 289:65-69 (1993).
31. Delikat, S. E., D. W. Galvani, and M. Zuzel: A function of CD10 on bone marrow stroma. Br. J. Haematol., 87:655-657 (1994).
32. Dickinson, J. L., E. J. Bates, A. Ferrantes, and T. M. Antalis: Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor-alpha induced apoptosis. J. Biol. Chem., 46:27894-27904 (1995).
33. DiMartino, M. J., W. High, W. A. Galloway, and M. J. Crimmin: Preclinical antiarthritic activity of matrix metalloproteinase inhibitors. Ann. N. Y. Acad. Sci., 732:411-413 (1994).
34. Dinarello, C. A.: Reduction of inflammation by decreasing production of IL-1 or by specific receptor antagonist. Int. J. Tissue React., 14:65-75(1992).
35. Dittel, B. N. and T. W. LeBien: The growth response to IL-7 during normal human B cell ontogeny is restricted to B-lineage cells expressing CD34. J. Immunol., 154:58-67 (1995).
36. Donnelly, R. P., S. Freeman, and M. Hayes: Inhibition of IL-10 expression by IFN-gamma up-regulates transcription of TNF-alpha in human monocytes. J. Immunol., 155:1420-1427 (1995).
37. Eccles, S. A., G. M. Box, W. J. Court, E. A. Bone, W. Thomas, and P. D. Brown: Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res., 56:2815-2822 (1996).
38. Edwards, D. R., P. P. Beaudry, T. D. Laing, V. Kowal, K. J. Leco, P. A. Leco, and M. S. Lim: The role of tissue inhibitors of metalloproteinases in tissue remodelling and cell growth. Int. J. Obesity, 20:S9-S15 (1996).
39. Egbert K. O., M. S. Baker, and S. L. Bunn: Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood, 86:4007-4027 (1995).
40. Ehl, S., U. Hoffmann-Rohrer, S. Nagata, H. Hengartner, and R. Zinkernagel: Different susceptibility of cytotoxic T cells to CD95 (Fas/APO-1 ligand mediated cell death after activation in vitro versus in vivo. J. Immunol., 156:2357-2360 (1996).
41. Fariss, R. N., S. S. Apte, B. R. Olsen, K. Iwata, and A. Milam: Tissue inhibitor of metalloproteinases-3 is a component of Bruch's membrane of the eye. Am. J. Pathol., 150:323-328 (1997).
42. French, L. E., M. Hahne, I. Viard, G. Raalgruber, R. Zanone, K. Becker, C. Muller, and J. Tschop: Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-priviledge tissues and co-expression in adult tissues characterized by apoptotic cell turnover. J. Cell Biol., 133:335-343 (1996).
43. Gatsios, P., H. D. Haubeck, E. Vandeleur, W. Frisch, S. S. Apte, H. Greiling, P. C. Heinrich, and Graeve: Oncostatin M differentially regulates tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2 gene expression in human synovial lining. Eur. J. Biochem., 241:56-63 (1996).
44. Gearing, A. J. H., P. Beckett, M. Christodoulou, M. Churchill, J. R. Clements, M. Crimmin, A. H. Davinson, A. H. Drummond, W. A. Galloway, R. Gilbert, J. L. Gordon, T. M. Leber, M. Mangan, K. Miller, P. Nayee, K. Owen, S. Patel, W. Thomas, G. Wells, L. M. Wood, and K. Woodlley: Matrix metalloproteinases and processing of pro-TNF-alpha. J. Leukoc. Biol., 57:774-777 (1995).
45. Gijbels, K., R. E. Galrdy, and L. Steinman: Reversal of experimental autoimmune encephalomyelitis with hydroximate inhibitor of matrix metalloproteinases. J. Clin. Invest., 94:2177-2182 (1994).
46. Giraudon, P., N. Thomasset, A. Bernard, B. Verrier, and M. F. Belin: Induction of MMP9 (92 kDa Gelatinase). Activity and expression of tissue inhibitor of metalloproteinase-2 mRNA (TIMP-2) in primitive neuroectodermal cells infected with retrovirus HTLV-1. Eur. J. Neurosci., 7:841-848 (1995).
47. Goetzl, E. J., M. J. Banda, and D. Leppert: Matrix metalloproteinases in immunity. J. Immunol., 156:1-4 (1996).
48. Greaves, M. F., G. Hairi, R. A. Newman, D. R. Sutherland, M. A. Ritter, and J. Ritz: Selective expression of the common acute lymphoblastic leukemia (gp100) antigen on immature lymphoid cells and their malignant counterparts. Blood, 61:628-639 (1983).
49. Greene, J., M. Wang, Y. E. Liu, L. A. Raymond, C. Rosen, and Y. E. Shi: Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J. Biol. Chem., 271:30375-30380 (1996).
50. Griffin, J. D., J. Ritz, L. M. Nadler, and S. F. Schlossman: Expression of myeloid differentiation antigens on normal and malignant myeloid cells. J. Clin. Invest., 68:932-941 (1981).
51. Griffith, T. S., T. Brunner, S. M. Fletcher, D. R. Green, and T. A. Ferguson: Fas ligand induced apoptosis as a mechanism of immune priviledge. Science, 270:1189-1192 (1995).
52. Grimaud, J. A. and H. Lortat-Jacob: Matrix receptors to cytokines. Path. Res. Pract., 190:883-890 (1994).
53. Hahne, M., D. Rimoldi, M. Schoter, P. Romero, M. Schreider, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J. C. Cerottini, and T. Bornand: Melanoma cell expression of FAS(APO-1)/CD95 ligand: implications for tumor immune escape. Science, 274:1302-1306 (1996).
54. Hammani, K., A. Blakis, D. Morsette, A. M. Bowcock, C. Scmutte, P. Henriet, and Y. A. DeClerk: Structure and characterization of the human tissue inhibitor metalloproteinase-2 gene. J. Biol. Chem, 271:25498-25505 (1996).
55. Hampson, I. N., L. Hampson, M. Pinkoski, M. Cross, C. M. Heyworth, R. C. Bleackley, E. Atkinson, and T. M. Dexter: Identification of a serpin specifically expressed in multipotent and bipotent hematopoietic progenitor cells and in activated T cells. Blood, 89:108-118 (1997).
56. Hayakawa, T., K. Yamashita, J. Kishi, and K. Harigaya: Tissue inhibitor of metalloproteinase-1 from a human bone marrow stromal cell line KM102 has erythroid potentiating activity, suggesting its possible functional role in hematopoietic environment. FEBS Lett., 268:125-128 (1990).
57. Hayakawa, T., K. Yamashita, K. Tanzawa, E. Uchijima, and K. Iawata: Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. FEBS, 298:29-32 (1992).
58. Hayakawa, T., K. Yamashita, E. Ohuchi, and A. Shinagawa: Cell growth promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J. Cell Sci., 107:2372-2379 (1994).
59. He, C. J., C. W. Yang, E. P Peten, Z. H. Liu, A. Patel, L. J. Striker, and G. E. Striker: Collagen and collagenase mRNAs in normal and sclerotic glomeruli: Predictors of progression and response to therapy. Kidney Int. Suppl., 49:539-543 (1995).
60. Heaney, M., and D. W. Golde: Soluble cytokine receptors. Blood, 87:847-857 (1993).
61. Hendrix, M. J. C., E. A. Seftor, T. M. Grogan, R. E. B. Seftor, E. M. Hersh, E. A. Boyse, L. A. Liotta, W. G., Stetler-Stevenson, and C. G. Ray: Expression of type IV collagenase correlates with the invasion of human lymphoblastoid cell lines and pathogenesis in SCID mice. Mol. Cell. Probes, 6:59-65 (1992).
62. Hormandberg, G. A. and F. Hui: Association of proteoglycan degradation with catabolic cytokine and stromelysin release from cartilage cultured with fibronectin fragmnets. Arch. Biochem. Bioph, 334:325-331 (1996).
63. Hurley, R. W., J. B. McCarthy, and C. M. Verfaillie: Direct adhesion to bone marrow via fibronectin receptors inhibits hematopoietic progenitors proliferation. J. Clin. Invest., 96:511-519 (1995).
64. Imren, S., D. B. Kohn, H. Shimada, B. Blavier, and Y. A. DeClerck: Overexpression of tissue inhibitor of metalloproteinases-2 by retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. Cancer Res., 56:2891-2895 (1996).
65. Inukai, T., K. Sugita, K. Iijima, T. Tezuka, K. Goi, S. Kojika, and K. Shiraishi: Expression of granulocyte colony- stimulating factor receptor on CD10-positive human B-cell precursors. Br. J. Haematol., 89:623-626 (1995).
66. Itoh, A., A. Mukaiyama, Y. Itoh, H. Nagase, I. B. Thogersen, J. J. Enghild, Y. Saaguri, and Y. Mori: Degradation of interleukin-1 beta by matrix metalloproteinases. J. Biol. Chem., 271:14657-14660 (1996).
67. Jarvis, L. J. and T. W. LeBien: Stimulation of human bone marrow stromal cell tyrosine kinases and IL-6 production by contact with B lymphocytes. J. Immunol., 155:2359-2368 (1995).
68. Johnson, M. D., H. C. Kim, L. Chesler, G. Tsao-Wu, N. Bouck, and P. J. Polverini: Inhibition of angiogenesis by tissue inhibitor of metalloproteinases. J. Cell. Physiol., 160:194-202 (1994).
69. Katsuda, S., Y. Okada, Y. Okada, K. Imai, and I. Nakanishi: Matrix metalloproteinase-9 (92-kd gelatinase/type IV collagenase equals gelatinase B) can degrade arterial elastin. Am. J. Pathol., 145:1208-1218 (1994).
70. Kawamata, H., K. Kawai, S. Kamayama, and M. D. Johnson: Overexpression of tissue inhibitor of matrix metalloproteinases (TIMP-1 and TIMP-2) suppresses extravasation of pulmonary metastasis of a rat bladder carcinoma. Int. J. Cancer, 63:680-687 (1995).
71. Kayagaki, N., A. Kawasaki, T. Ebata, H. Ohmoto, S. Ikeda, S. Inoue, K. Yoshino, K. Okumura, and H. Yagita: Metalloproteinase mediated release of human Fas ligand. J. Exp. Med., 182:1777-1783 (1995).
72. Keating, A., C. K. Whalen, and J. W. Singer: Cultured stromal cell express common acute lymphoblastic leukemia antigen (CALLA): Implications for marrow transplantation. Br. J. Haematol., 55:623-628 (1983).
73. Kerst, J. M., J. B. Sanders, I. C. Slaper-Cortenbach, M. C. Doorkkers, B. Hooibrink, R. H. Van Oers, A. E. von dem Borne, and C. E. van der School: Alpha 4 beta 1 and alpha 5 beta 1 are differentially expressed during myelopoiesis and mediate the adherence of human CD34+ cells to fibronectin in an activation-dependent way. Blood, 81:344-351 (1993).
74. Khokha, R., P. Waterhouse, S. Yagel, P. K. Lala, C. M. Overall, G. Norton, and D. T. Denhardt: Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science, 243:947-950 (1989).
75. Khokha, R., M. J. Immer, C. H. Graham, P. K. Lala, and P. Waterhouse: Suppression of invasion by inducible expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in B16-F10 melanoma cells. J. Natl. Cancer Inst., 84:1017-1023 (1994).
76. Khokha, R., M. J. Zimmer, S. M. Wilson, and A. F. Chambers: Up-reulation of TIMP-1 expression in B16-F10 melanoma cells suppresses their metastatic ability in chick embryos. Clin. Exp. Metast., 10:365-370 (1992).
77. Kinoshita, T., H. Sato, T. Takino, and M. Itoh: Processing of a precursor of 72-kilodalton type IV collagenase/gelatinase A by a recombinant membrane-type 1 matrix metalloproteinase. Cancer Res., 56:2535-2538 (1996).
78. Kishnani, N. S., P. W., Staskus, T-T. Yang, F. R. Masiarz, and S. P. Hawkes: Identification and characterization of human tissue inhibitor of metalloproteinase-3 and detection of three additional metalloproteinase inhibitor activities in extracellular matrix. Matrix. Biol., 14:479-488 (1994).
79. Klein, G.: The extracellular matrix of the hematopoietic microenvironment. Experientia, 51:914-922 (1995).
80. Kleiner, D. E., Jr., A. Tuhila, K. Tryggvason, and W. G. Stetel-Stevenson: Stability analysis of latent and active 72 kDa type IV collagenase: the role of tissue inhibitor of metalloproteinases-2 (TIMP-2). Biochemistry, 32:1583-1592 (1993).
81. Kobayashi, M., J-I. Hamada, Y. Li, N. Shinobu, M. Imamura, O. Futoshi, N. Takeichi, and M. Hosokawa: A possible role of 92 kDa type IV collagenase in the extramedullary tumor formation in leukemia. Jpn. J. Cancer Res., 86:298-303 (1995).
82. Koop, S., R. Khokha, E. E. Schmidt, I. C. MacDonald, V. L. Morris, A. F. Chambers, and A. C. Groom: Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res., 54:4791-4797 (1994).
83. Kossakowka, A. E., S. J. Urbanski, and D. R. Edwards: Tissue inhibitor of metallo-proteinases-1 (TIMP-1) RNA is expressed at elevated levels in malignant non-Hodgkin's lymphomas. Blood, 77:2475-2481 (1991).
84. Kossakowska, A. E., S. J. Urbanski, S. A. Huchcroft, and D. R. Edwards, Relationship between the clinical aggressiveness of large cell immunoblastic lymphomas and expression of 92 kDa gelatinase (Type IV collagnase) and tissue inhibitor of metalloproteinases-1 (TIMP-1) RNAs. Oncol. Res., 4:233-240 (1992).
85. Kossakowska, A. E., S. J. Urbanski, A. Watson, L. J. Hayden, and D. R. Edwards: Patterns of expression of metalloproteinases and their inhibitors in human malignant lymphomas. Oncol. Res., 5:19-28 (1993).
86. Krizanac-Bengez, L. and M. Boranic: Enkephalinase-blocking agent thiophan affects cell growth and differentiation in long-term culture of mouse bone marrow. Biomed. Pharmacother., 49:375-380 (1995).
87. Lacraz, S., L. Nicod, R. Chicheportiche, H. Welgus, and J. M. Dayer: IL-10 inhibits metalloproteinases and stimulates TIMP-1 production in human mononuclear phagocytes. J. Clin. Invest., 96:2304-2310 (1995).
88. Lacraz, S., L. Nicod, B. Galve-de Rochemontoix, and C. Baunmberger: Suppression of metalloproteinase biosynthesis in human alveaolar macrophages by IL-4. J. Clin. Invest., 90:382-388 (1992).
89. Lafleur, M., J. L. Underwood, D. A. Rappolee, and Z. Werb: Basement-membrane and repair of injury to peripheral nerve defining a potential role for macrophages, matrix metalloproteinases, and tissue inhibitor of metalloproteinases-1. J. Exp. Med., 184:2311-2326 (1996).
90. Larsen, S. L., L. O. Pederson, S. Buus, and A. Stryhn: T cell responses affected by aminopeptidase (CD13)- mediated trimming of major histocompatibility complex class II-bound peptides. J. Exp. Med., 184:183-189 (1996)
91. Leco, K. J., R. Khokha, N. Pavloff, S. P. Hawkes, and D. R. Edwards: Tissue inhibitor of metalloproteinases-(TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells. J. Biol. Chem., 269:9352-9360 (1994).
92. Leppert, D., E. Waubant, R. Galardy, N. Bunnett, and S. L. Hauser: T cell gelatinases mediate basement membrane transmigration in vivo. J. Immunol., 154:4379-4389 (1995).
93. Leppert, D., S. L. Hauser, J. L. Kishiyama, A. An., L. Zeng, and E. J. Goetzl: Stimulation of matrix metalloproteinase-dependent migration of T cells by eicosanoids. FASEB J., 9:1473-1481 (1995).
94. Levesque, J. P., D. N Haylock, and P. J. Simmons: Cytokine regulation of proliferation and cell adhesion are correlated events in human CD34+ hematopoietic progenitors. Blood, 88:1168-1176 (1996).
95. Levi, E., R. Fridman, H. Q. Miao, Y. S. Ma, A. Yayon, and I. Vlodavsky: Matrix metalloproteinase-2 releases active soluble ectodomain of fibroblasts growth factor receptor 1. Proc. Natl. Acad. Sci. U.S.A., 93:7069-7074 (1996).
96. Lochter, A. and Bissell M. J.: Involment of extracellular matrix constituents in breast cancer. Semin. Cancer Biol., 6:165-173 (1995).
97. Malik, N. B., W. Greenfield, A. F. Wahl, and P. A. Kiener: Activation of human monocytes through CD40 induces matrix metalloproteinases. J. Immunol., 156:3952-3960 (1996).
98. Mariani, S.M., B. Matiba, C. Baumler, and P. H. Krammer: Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteinases. Eur. J. Immunol., 25:2303-2307 (1995).
99. Matsuzaki, A. and A. Janowska-Wieczorek: Unstimulated human myelogenous leukemia blasts secret matrix metalloproteinases. J. Cancer Clin. Oncol., 123:100-106 (1997).
100. Mauviel, A.: Cytokine regulation of metalloproteinase gene expression. J. Cell Biochem., 53:288-295 (1993).
101. McGeehan, G. M., J. D. Becherer, R. C. Bast, C. M. Boyer, B. Champion, K. M. Connolly, J. G. Conway, F. Furdon, S. Karp, S. Kidao, A. B. McElroy, J. Nichols, K. M. Pryzwansky, F. Schoenen, L. Sekut, A. Truesdale, M. Verghese, J. Warner, and J. Ways : Regulation of tumor necrosis factor-alpha processing by metalloproteinase inhibitor. Nature, 370:558-561 (1994).
102. Montgomery, A. M. P., H. Sabzevari, and R. A. Reisfeld: Production and regulation of gelatinase B by human T-cells. Biochim. Biophys. Acta., 1176:265-268 (1993).
103. Montgomery, A. M., B. M. Mueller, R. A. Resifeld, S. M. Taylor, and Y. DeClerk: Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res., 54:5467-5473 (1994).
104. Moses, M. A., J. Sudhalter, and R. Langer: Identification of an inhibitor of neovascularization from cartilage. Science, 248:1408-1410 (1990).
105. Mullberg, J., F. H. Durie, C. Otten-Evans, M. R. Alderson, S. Rose-John, D. Cosman, R. A. Black, and K. M. Mohler: A metalloproteinase inhibitor blocks shedding of IL-6 receptor and the p60 TNF receptor. J. Immunol., 155:5198-5205 (1995).
106. Murate, T., K. Yamashita, H. Ohashi, Y. Kagami, K. Tsushita, T. Kinoshita, T. Hotta, H. Saito, S. Yoshida, K. J. Mori, and T. Hayakawa: Erythroid potentiating activity of tissue inhibitor of metalloproteinases on the differentiation of erythroipoietin-responsive mouse erythroleukemia cell line, ELM-I-1-3, is closely related to its cell growth potentiating activity. Exp. Hematol., 21:169-176 (1993).
107. Murphy, G., A. Houbrechts, M. I. Cockett, R. A. Williamson, M. O'Shea, and A. J. P. Docherty: The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry, 30:8097-8102 (1991).
108. Murphy, A. N., E. J. Unsworth, and W. G. Stetler-Stevenson: Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J. Cell. Physiol., 157:351-358 (1993).
109. Nemeth, J. A. and C. L. Goolsby: TIMP-2, a growth-stimulatory protein from S V40-transformed human fibroblats. Exp. Cell Res., 207:376-383 (1993).
110. Nemeth, J. A., B. Fare, M. Steiner, and C. L. Goolsby: TIMP-2 growth-stimulatory activity: a concentration-and cell type-specific response in the presence of insulin. Exp. Cell. Res., 224:110-115 (1996).
111. Nikkari, S. T., M. Hoyhtya, J. Isola, and T. Nikkari: Machrophages contain 92-kDa gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis. Am. J. Path., 149:1427-1433 (1996).
112. Niskanen, E., J. C. Gasson, C. D. Teates, and D. W. Golde:. In vivo effect of human erythroid-potentiating activity on hematopoiesis in mice. Blood, 72:806-810 (1988).
113. Nomura, S., A. J. Wills, D. R. Edwards, J. K. Heath, and B. L. Hogan: Expression of genes for noncollagenous proteins during embryonic bone marrow formation. Connect. Tissue Res., 21:31-35 (1989).
114. Okada, A., J. P. Bellocq, N. Rouyer, M. P. Chenard, M. C. Rio, P. Chambon, and P. Basset: Membrane type matrisxmetalloproteinases (MT-MPP) gene is expressed by stromal cells of human colon, breast and head and neck carcinomas. Proc. Natl. Acad. Sci. U.S.A., 92:2730-2734 (1995).
115. O'Shea, M., F. Willenbrock, R. A. Williamson, M. I. Cockett, R. B. Freedman, J. J. Reynolds, A. J. P. Docherty, and G. Murphy: Site-directed mutations that alter the inhibitory activity of the tissue inhibitor of metalloprotienases-1: importance of the N-terminal region between cysteine 3 and cysteine 13. Biochemistry, 31:10146-10152 (1992).
116. Pavloff, N., P. W. Staskus, N. S. Kishnani, and S. P. Hawkes: A new inhibitor of metalloproteinases from chicken, ChiMP-3: a third member of the TIMP family. J. Biol. Chem., 267:17321-17326 (1992).
117. Pei, D. and S. J. Weiss: Furin-dependent intracellular activation of the human stromelysin 3 zymogen. Nature, 375:244-247 (1995).
118. Pluznik, D. H., R. Fridman, and R. Reich: Correlation in the expression of type IV collagenase and the invasive and chematotactic abilities of myelo-monocytic cells during differentiation into macrophages. Exp. Hematol., 20:57-63 (1992).
119. Preece, G., G. Murphy, and A. Ager: Metalloproteinase-mediated regulation of L-selectin levels on leukocytes. J. Biol. Chem., 17:11634-11640 (1996).
120. Rao, J. S., P. A. Steck, P. Tofilon, and D. Boyd: Role of plasminogen activator and of 92-kDa type IV collagenase in glioblastoma invasion using an in vitro matrigel model. J. Neurol. Oncol., 18:129-138 (1993).
121. Reynolds, J. J., R. M. Hembry, and M. L. Meikle: Connective tissue degradation in health and periodontal disease and the roles of matrix metalloproteinases and their natural inhibitors. Adv. Dent. Res., 8:312-319 (1994).
122. Ries, C., H. Kolb, and P. E. Petrides: Regulation of 92-kDa gelatinase release in HL-60 leukemia cells: tumor necrosis factor as an autocrine stimulus for basal-and phorbol ester-induced secretion. Blood, 83:3638-3646 (1994).
123. Ries, C., F. Lottspeich K. H. Dittman, and P. E. Petrides: HL-60 leukemia-cells produce an autocatalytically truncated form of matrix metalloproteinase-9 with impaired sensitivity to inhibition by tissue inhibitors of metalloproteinases. Leukemia, 10:1520-1526(1996).
124. Ries, C. and P. E. Petrides: Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol. Chem. Hoppe Seyler, 376:345-355 (1995).
125. Ritz, J., L. Naddler, A. Bhan, J. Notis-McCornaty, J. Pessando, and S. F. Schlossman: Expression of a common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage. Blood, 58:648-652 (1981).
126. Roeb, E., J. S. Rose, A. Erren, D. R. Edwards, S. Matern, L. Graeve, and P. C. Heinrich: Tissue inhibitor of metalloproteinases-2 (TIMP-2) in rat liver cells is increased by lipopolysaccharide and prostaglandin E2. FEBS Lett., 357:33-36 (1995).
127. Roeb, E., L. Graeve, R. Hoffman, K. Decker, D. R. Edwards, and P. C. Heinrich: Regulation of tissue inhibitor of metalloproteinases-1 gene expression by cytokines and dexamethasone in rat hepatocyte primary cultures. Hepatology, 18:1437-1442 (1993).
128. Romanic, A. M. and J. A. Madri: The induction of 72-kDa gelatinase in T cells upon adhesion to endothelial cells is VCAM-1 dependent. J. Cell Biol., 125:1165-1178 (1994).
129. Rosenberg, G. A., J. E. Dencoff, P. G. McGuire, L. A. Liotta, and W. G. Stetler-Stevenson: Injured-induced 92-Kilodalton gelatinase and urokinase expression in rat brain. Lab. Invest., 71:417-422 (1994).
130. Ruiz, A., P. Brett, and D. Bok: TIMP-3 is expressed in the human retinal-pigment epithelium. Biochem. Bioph. Res. Comm., 226:467-474 (1996).
131. Sackstein, R.: Expression of an L-selectin ligand on hematopoietic progenitors cells. Acta Haematol., 97:22-28 (1997).
132. Sakai, K., T. Hahaori, K. Sagawa, M. Yokoyama, and K. Takatsuki: Biochemical and functional characterization of MCS-2 antigen (CD13) on myeloid leukemic cells and polymorphonuclear leukocytes. Cancer Res., 47:5572-5576 (1987).
133. Salles, G., C. Y. Chen, E. L. Reinherz, and M. A. Shipp: CD10/NEP is expressed on thy-low B220+ murine B cell progenitors and functions to regulate stromal cell dependent lymphopoiesis. Blood, 80:2021-2029 (1992).
134. Saren, P., H. G. Welgus, and P. T. Kovanen: TNF-alpha and IL-1 beta selectively induce expression of 92-kDa gelatinase by human macrophages. J. Immunol., 157:4159-4165 (1996).
135. Sato, H., T. Kinoshita, T. Takino, K., Nakayama, and M. Seiki: Activation of a recombinant membrane type-1 matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP-2). FEBS Lett., 393:101-104 (1996).
136. Schultz, R. M., S. Silberman, B. Persky, A. S. Bajkowsko, and D. F. Carmichael: Inhibition by human recombinant tissue inhibitor of metallopro-teinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells. Cancer Res., 48:5539-5545 (1988).
137. Semenza, G.: Anchoring and biosynthesis of stalked brush border membrane proteins: glycosidases and peptidases of enterocytes and renal tubuli. Ann. Rev. Cell Biol., 2:255-313 (1986).
138. Shapiro, S. D., E. J. Campbell, H. G. Welgus, and R. M. Senior: Elastin degradation by mononuclear phagocytes. Ann. N.Y. Acad. Sci., 624:69-80 (1991).
139. Sherwood, P. J. and I. L. Wesissman: The growth factor IL-7 induces expression of a transformation associated antigen in normal pre-B cells. Int. Immunol., 2:399-404 (1990).
140. Shi, W., B. Mognetti, A. Campana, and P. Bischof: Metalloproteinase secretion by endometrial leukocyte subsets. Am. J. Reprod. Immunol., 34:299-310 (1995).
141. Shipp, M. and T. Look: Hematopoietic differentiation antigens that are membrane associated enzymes: Cutting is the key? Blood, 82:1052-1070 (1993).
142. Shipp, M. A., G. E. Tarr, C. Y. Chen, S. N. Switzer, L. B. Hersh, H. Stein, and E. L. Reinherz: CD10/NEP hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc. Natl. Acad. Sci. U.S.A., 88:10662-10666 (1991).
143. Sobol, R. E., R. Mick, I. Royston, F. R. Davey, R. R. Ellison, R. Newman, H. Colins, D. A. Nelson, and C. D. Bloomfield: Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemias. N. Engl. J. Med., 316:1111-1117 (1987).
144. Stetler-Stevenson, M., A. Mansoor, M. S. Lim, P. Fukushima, J. Kehrl, G. Marti, K. Ptaszynski, J. Wang, and W. G. Stetler-Stevenson: Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases (TIMPs) in reactive and neoplastic lymphoid cells. Blood, 89: in press (1997).
145. Stetler-Stevenson, W. G., H. C. Krutzsch, and L. A. Liotta: Tissue inhibitor of metalloproteinase (TIMP-2). J. Biol. Chem., 264:17374-17378 (1989).
146. Stetler-Stevenson, W. G.: Progelatinase A activation during tumor cell invasion. Invasion Metast., 14:259-268 (1994).
147. Stetler-Stevenson, W. G.: Dynamics of matrix turnover during pathologic remodeling of extracellular matrix. Am. J. Path., 148:1345-1350 (1996).
148. Stetler-Stevenson, W. G., N. Bersch, and D. W. Golde: Tissue inhibitor of metalloproteinase-2 (TIMP-2) has erythroid-potentiating activity. FEBS Lett., 296:231-234 (1992).
149. Stetler-Stevenson, W. G., S. Aznavoorian, and L. A. Liotta: Tumor cell interactions with the extracellular matrix during invasion and metastasis. Ann. Rev. Cell Biol., 9:541-573 (1993).
150. Stetler-Stevenson, W. G., R. Hewitt, and M. Corcoran: Matrix metalloproteinases and tumor invasion: from correlation to casuality to clinic. Semin. Cancer Biol., 7:147-154 (1996).
151. Takahashi, G., D. Moran, D. F. Andrews, and J. Singer: Differential expression of collagenase by human fibroblasts and bone marrow stromal cells. Leukemia, 8:305-308 (1994).
152. Taki, T., K. Ida, F. Bessho, R. Hanada, A. Kikuchi, K. Yamamoto, M. Sako, M. Tsuchida, M. Seto, and Y. Hayashi: Frequency and clinical significance of the MLL gene rearrangements in infant acute leukemia. Leukemia, 10:1303-1307 (1996).
153. Tanaka, M., T. Suda, K. Haze, N. Nakamura, N. Sato, F. Kimura, K. Motoyoshi, M. Mizuki, S. Tagawa, S. Ohga, K. Hatake, A. Drummond, and S. Nagata: Fas ligand in human serum. Nature Med., 2:317-322 (1996).
154. Tanaka, M., T. Suda, T. Takahashi, and S. Nagata: Expression of functional soluble form of human Fas ligand in activated lymphocytes. EMBO J., 14:1129-1135 (1995).
155. Taraboletti, G., A. Garofalo, D. Belotti, T. Drudis, P. Borsotti, E. Scanziani, P. D. Brown, and R. Giavazzi: Inhibition of angiogenesis and murine hemangioma growth by Batimastat, a synthetic inhibitor of matrix
156. Uchijima, M., H. Sato, M. Fujii, and M. Seiki: Tax proteins of Human T-cell Leukemia Virus type 1 and 2 induce expression of the gene encoding erythroid-potentiating activity (Tissue inhibitor of metalloproteinases-1, TIMP-1). J. Biol. Chem., 269:14946-14950 (1994).
157. Van Wart, H. and H. Birkedal-Hansen: The cysteine switch: a principal regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinases gene family. Proc. Natl. Acad. Sci. U.S.A., 87:5578-5582 (1990).
158. Verfaillie, C. M., J. B. McCarthy, and P. B. McGlave: Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia: decreased adhesion to the basement membrane components laminin and collagen type IV. J. Clin. Invest., 90:1232-1239 (1992).
159. Verfaillie, C., R. Hurley, R. Bhatia, and J. McCarthy: Role of bone marrow matrix in normal and abnormal hematopoiesis. Crit. Rev. Oncol. Hematol., 16:201-224 (1994).
160. Vollmer, P., I. Walev, S., R. J. Sma, and S. Bhakdi: Novel pathogenic mechanism of microbial metallo- proteinases: liberation of membrane-anchored molecules in biologically active form exemplified by studies with human interleukin-6 receptor. Infect. Immun., 64:3646-3651 (1996).
161. Wahl, L. M. and M. L. Corcoran: Regulation of monocyte/ macrophage metalloproteinase production by cytokines. J. Periodont., 64:467-473 (1993).
162. Wang, X., X. Fu, P. D. Brown, M. J. Crimmin, and R. M. Hoffman: Matrix metalloproteinase inhibitor BB-94 (Batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res., 54:4726-4728 (1994).
163. Watanabe, H., I. Nakanishi, K. Yamashita, T. Hayaka, and Y. Okada: Matrix metalloproteinase-9 (92 kDa gelatinase/type IV collagenase) from U937 monoblastoid cells: correlation with cellular invasion. J. Cell. Sci., 104:991-999 (1993).
164. Watson, S. A., T. M. Morris, S. L. Parsons, R. J. C. Steele, and P. D. Brown: Therapeutic effect of the matrix metalloprotteinase inhibitor, batimastat, in a human colorectal cancer ascites model. Br. J. Cancer, 74:1354-1358 (1996).
165. Werb, Z. J. Ashkenas, and J. F. Mecanley: Extracellular matrix remodeling as a regulator of stromal-epithelial interactions during mammary gland development, involution, and carcinogenesis. Brazilian J. Med. Biol. Res., 29:1087-1097 (1996).
166. Wick, M., C. Burger, S. Brasselbach, F. C. Luicibello, and R. A. Muller: A novel member of the human tissue inhibitor of metalloproteinases (TIMP) gene family is regulated during G1 progression, mitogenic stimulation, differentiation and senescence. J. Biol. Chem., 269:18953-18960 (1994).
167. Williams, L. M., D. L. Gibbons, A. Gearing, R. N. Maini, M. Feldman, and F. M. Brennan: Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures. J. Clin. Invest., 97:2833-2841 (1996).
168. Wills, A., N. M. Thompson, M. Crowther, N. P. Brindle, A. Nasim, R. D. Sayers, and P. R. F. Bell: Elastase-in- duced matrix degradation in arterial organ cultures: an in vitro model of aneurysmal disease. J. Vasc. Surg., 24:667-679 (1996).
169. Woessner, J. F.: Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB, 5:2145-2153 (1991).
170. Xia, M., D. Leppert, S. L. Hauser, S. P. Sreedhara, P. J. Nelson, A. M. Krensky, and E. J. Goetzl: Stimulus specificity of matrix metalloproteinase dependence of human T cell migration through a model basement membrane. J. Immunol., 156:160-167 (1996).
171. Yang, B., C. L. Hall, B. L. Yang, R. C. Savani, and E. A. Furley: Identification of a novel heparin domain in RHAMM and evidence that it modifies HA-mediated locomotion of ras-transformed cells. J. Cell Biochem., 56:455-468 (1994).
172. Yang, T-T. and S. P. Hawkes: Role of the 21-kDa protein TIMP-3 in oncogenic transformation of cultured chicken embryo fibroblasts. Proc. Natl. Acad. Sci. U.S.A., 89:10676-10680 (1992).
173. Yoder, M. and D. A. Williams: Matrix molecules interactions with hematopoietic stem cells. Exp. Hematol., 23:961-967 (1995).
174. Yoshizaki, T., H. Sato, Y. Maruyama, S. Murono, M. Furukawa, C-S. Park., and M. Seiki: Increased expression of membrane type 1-matrix metalloproteinase in head and neck carcinoma. Cancer, 79:139-144 (1997).
175. Zeng, L., S. An, and E. J. Goetzl: Selective regulation of RNK-16 cell matrix metalloproteinases by the EP4 subtype of protaglandine E2 receptor. Biochemistry, 35:7159-7164 (1996).
176. Zempo, N., N. Koyama, R. D. Kenagy, H. J. Lea, and A. W. Clowes: Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metallo-proteinases inhibitor. Arterioscler. Tromb. Vas. Biol., 16:28-33 (1996).
177. Zhou, H., E. J. Bernhard, F. E. Fox, and P. C. Billings: Induction of metalloproteinase activity in human T-lymphocytes. Biochim. Biophys. Acta., 1177:174-178 (1993).